D. R. Budman

HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer

Donald A. Berry, Hyman B. Muss, Ann D. Thor et al. · Journal of Clinical Oncology · 2000 · 181 citations

Medicine, Oncology, Pharmacology +16

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes

I. Shapira, Michaela Oswald, John L. Lovecchio et al. · British Journal of Cancer · 2013 · 150 citations · Full text

Medicine, Gynecology, Oncology +17

Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Lynn G. Dressler, Donald A. Berry, Gloria Broadwater et al. · Journal of Clinical Oncology · 2005 · 106 citations · Full text

Medicine, Cancer Biology, Oncology +17

Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.

Long G. Wang, Xiao M. Liu, Willi Kreis et al. · PubMed · 1997 · 69 citations

Life Sciences, Endocrinology, Molecular Biology +17

Handbook of Anticancer Drug Development

D. R. Budman, A H Calvert, Eric K. Rowinsky et al. · Anti-Cancer Drugs · 2004 · 54 citations

Medicine, Cancer Biology, Oncology +12